Drug Delivery in Chronic Inflammatory Respiratory Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 3845
Special Issue Editors
Interests: bacterial proteins; Streptococcus pneumoniae; pneumolysin; chronic obstructive lung disease; prolyl oligopeptidase; poly(prolylprolylglycine)15; exosomes; extracellular vesicles; microRNA
Special Issue Information
Dear Colleagues,
I am putting together a Special Issue titled “Drug Delivery in Chronic Inflammatory Respiratory Diseases” that I think may be of interest to you. I invite you to submit a manuscript for consideration and possible publication in this Special Issue of Pharmaceutics. Chronic inflammatory diseases of the lung are a major health burden worldwide, and the need for better treatments and mechanisms to deliver these therapeutics are in high demand. This Special Issue aims to highlight research into new drug targets for diseases such as asthma, fibrosis, and COPD, among others, as well as novel methods for the delivery and manufacture of these therapies, including nanoparticle delivery via extracellular vesicles. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: novel drug discovery, delivery mechanisms (including extracellular vesicle delivery), newly identified targets for drug design, and therapy/treatments for chronic lung inflammation.
I look forward to receiving your contributions.
Dr. Kristopher Genschmer
Dr. Camilla Margaroli
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- COPD
- IPF
- asthma
- extracellular vesicles
- drug delivery
- inflammation
- lung disease therapeutics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
